KCA
YARW

KVP Capital Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

KVP Capital Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$299K Hold
10,011
– – 0.22% 32
2025
Q4 		$290K Buy
+10,011
New +$201K 0.28% 27

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KVP Capital Advisors's YARW Position: Q1 2026 in Review

KVP Capital Advisors held its Yarrow Bioscience, Inc. Common Stock (YARW) position steady in Q1 2026 at 10,011 shares worth $299K. The position accounts for 0.22% of the portfolio, ranked #32.

KVP Capital Advisors first reported a position in YARW in Q4 2025 and has held it in 2 quarters since. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • KVP Capital Advisors held 10,011 shares of Yarrow Bioscience, Inc. Common Stock worth $299K as of Q1 2026.
  • KVP Capital Advisors left its Yarrow Bioscience, Inc. Common Stock share count unchanged in Q1 2026.
  • Yarrow Bioscience, Inc. Common Stock made up 0.22% of KVP Capital Advisors's portfolio in Q1 2026, its #32 holding.
  • KVP Capital Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q4 2025 and has held it in 2 quarters since.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on KVP Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.